Cells and tissues are not only defined by their molecular composition but also by their mechanical properties, key drivers of function, disease progression, and therapeutic response. This panel brings together leading academic and industry experts to explore how advances in accessible, automated AFM technologies are opening mechanobiology to a much broader range of researchers.
Tuesday, May 5, 13:00 - 13:45, room Shanghai 1+2
| Name | Position | Institution |
|---|---|---|
| Dr. Marko Loparic | Co-Founder, CMO and Head of Digital Health | Artidis |
| Name | Position | Institution |
|---|---|---|
| Prof. Roderick Lim | Head of Research Group Nanobiology | Biozentrum Basel |
| Prof. Dr. Laura Suter-Dick | Head of Research Group Cell Biology and In Vitro Toxicology | FHNW |
| Dr. Salvatore Piscuoglio | Associate Professor of Genetics at the Humanitas University, Group Leader at the Humanitas Research Hospital, Head Precision Medicine Research Lab | HUMANITAS |
| Samantha Paoletti | Head Research & Business Development, Life Science Technologies | CSEM |
| Dr. Valeria Panzetta | Assistant Professor | University of Naples Federico II |
Artidis® is a pioneering clinical stage health technology company that aims to set the gold standard in tissue analysis and therapy optimization. By combining its nanotechnology platform for rapid tissue analysis with a holistic data solution, Artidis® accelerates drug discovery, tissue engineering, and
personalized treatment. Artidis® focuses its research and development efforts on solid tumors to enhance responses to chemo, immuno, and cell therapies, driving precision in cancer care. The company has offices in Basel (Switzerland), Barcelona (Spain), and Houston (Texas, US).
